Axogen, Inc.

AXGN · NasdaqCM · Stock · Healthcare
$35.14
-2.85% today
Delayed price,

What Axogen does

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$2.06B
P/E (ttm)
—
Forward P/E
48.7
Dividend yield
0.00%
Beta
1.17
Profit margin
-13.4%
Employees
622
Headquarters
Alachua, FL, United States
Exchange
NasdaqCM

Performance

1 Month
-20.6%
3 Months
-11.8%
6 Months
-8.7%
1 Year
+111.8%
5 Years
+267.2%
$16.2452-week range$52.91
Biggest setback — last 12 months
-31.7%
24 Aug 2026 → 12 Oct 2026
Fell from $51.47 to $35.14 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+210.2%
13 Oct 2025 → 24 Aug 2026
Ran from $16.59 to $51.47 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Below long-term trend
Price sits below its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$30.19 (-14.1%)$35.14$40.91 (+16.4%)
3 Months$27.01 (-23.1%)$35.14$45.72 (+30.1%)
6 Months$24.22 (-31.1%)$35.14$50.98 (+45.1%)
12 Months$20.76 (-40.9%)$35.14$59.48 (+69.3%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 52.6%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.